Replies to post #394607 on NorthWest Biotherapeutics Inc (NWBO)

[Dr Bala]

Not only that Flip; even if you throw in the IDH mutants into the pile, the current SOC won't significantly alter the statistics of the control arm because of the low percentage (around 5%) of the IDH mutant patients.

[exwannabe]

NWBO is also comparing treatment to placebo. I’d think you and ex wouldn’t have to be told that nine billion times.

The trial, like most all trials, has many secondary and tertiary endpoints. But the trial passes or fails with the primary (or more precisely, however the alpha is assigned).

If they do change the endpoints in the analysis, then they can properly say they trial worked if it meets the OS against historical trials endpoint.

The FDA would not fall for that game, but a subset of investors will.